×
ADVERTISEMENT

cytomegalovirus

New Indication for Prevymis to Prevent CMV in High-Risk Kidney Transplant Recipients

The FDA granted a new indication for letermovir for prophylaxis of CMV disease in high-risk adult kidney transplant ...

JUNE 6, 2023

FDA Approves Livtencity for Resistant Post-Transplant CMV

Although a rare disease overall, CMV is one of the most common infections experienced by both HSCT and SOT ...

NOVEMBER 24, 2021

CMV Reactivation and Rx After Allo-HCT Pose Substantial Toll

Reactivation of CMV infection and preemptive therapy to prevent progression to CMV disease in allo-HCT recipients ...

MARCH 26, 2018

FDA Approves Prevymis to Prevent CMV Among Stem Cell Transplant Patients

The FDA approved Merck's Prevymis, Merck for prophylaxis of cytomegalovirus infection and disease in adult ...

NOVEMBER 9, 2017

Load more